Overview:
The approval represents a breakthrough in the treatment of HIV-positive people, as it combines two antiretroviral drugs in a single pill. The possibility of single doses simplifies treatment and patient compliance.
Introduction
Brazil’s National Health Surveillance Agency (Anvisa) has approved a new drug for the treatment of HIV that combines two different substances in a single tablet.
The new drug is a combination of the substances Lamivudine and Dolutegravir sodium.
The approval represents a breakthrough in the treatment of people with the virus that causes AIDS, since it combines in a daily dose two antiretroviral drugs that were not available in a single pill.
The possibility of single doses simplifies treatment and patient compliance.
The package insert approved by the Agency (Anvisa)
- The new drug reduces the amount of HIV in the body.
- It promotes an increase in the white blood cell count (DC4).
For more information, about the Bula Approved by Anvisa , click here (available only in Portuguese).
New Drug
Will be complete for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in adults and adolescents over the age of 12 weighing at least 40 kg with no history of prior antiretroviral treatment or as a substitute for the current antiretroviral regimen in persons with virologic suppression.
Drug Registration
Granted to the laboratory GlaxoSmithKline Brasil Ltda.
References
Ministry of Health – Anvisa Section. For the link, click here (available only in Portuguese).
About Global Regulatory Partners
Global Regulatory Partners Inc, (GRP) is an American company that provides regulatory affairs, clinical, quality and safety services to medical devices, pharmaceutical, cosmetic and Food Supplement companies globally.
GRP headquarters is located in Massachusetts USA and its main affiliates are located in China, Japan, Brazil, and Mexico. GRP helps many life science companies register their products in different countries in compliance with local regulations.